Prolactin receptor attenuation induces zinc pool redistribution through ZnT2 and decreases invasion in MDA-MB-453 breast cancer cells

Exp Cell Res. 2014 Feb 15;321(2):190-200. doi: 10.1016/j.yexcr.2013.12.005. Epub 2013 Dec 11.

Abstract

Prolactin receptor (PRL-R) activation regulates cell differentiation, proliferation, cell survival and motility of breast cells. Prolactin (PRL) and PRL-R over-expression are strongly implicated in breast cancer, particularly contributing to tumor growth and invasion in the more aggressive estrogen-receptor negative (ER-) disease. PRL-R antagonists have been suggested as potential therapeutic agents; however, mechanisms through which PRL-R antagonists exert their actions are not well-understood. Zinc (Zn) is a regulatory factor for over 10% of the proteome, regulating critical cell processes such as proliferation, cell signaling, transcription, apoptosis and autophagy. PRL-R signaling regulates Zn metabolism in breast cells. Herein we determined effects of PRL-R attenuation on cellular Zn metabolism and cell function in a model of ER-, PRL-R over-expressing breast cancer cells (MDA-MB-453). PRL-R attenuation post-transcriptionally increased ZnT2 abundance and redistributed intracellular Zn pools into lysosomes and mitochondria. ZnT2-mediated lysosomal Zn sequestration was associated with reduced matrix metalloproteinase 2 (MMP-2) activity and decreased invasion. ZnT2-mediated Zn accumulation in mitochondria was associated with increased mitochondrial oxidation. Our results suggest that PRL-R antagonism in PRL-R over-expressing breast cancer cells may reduce invasion through the redistribution of intracellular Zn pools critical for cellular function.

Keywords: Breast cancer; Lysosomes; MMP-2; Mitochondria; PRL-R; ZnT2.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biological Transport / drug effects
  • Breast Neoplasms / genetics
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / pathology*
  • Cation Transport Proteins / physiology*
  • Female
  • Hormone Antagonists / pharmacology*
  • Humans
  • Mitochondria / drug effects
  • Mitochondria / metabolism
  • Neoplasm Invasiveness
  • Oxidation-Reduction / drug effects
  • RNA, Small Interfering / genetics
  • Receptors, Prolactin / antagonists & inhibitors*
  • Receptors, Prolactin / genetics
  • Tissue Distribution / drug effects
  • Tumor Cells, Cultured
  • Zinc / metabolism*

Substances

  • Cation Transport Proteins
  • Hormone Antagonists
  • RNA, Small Interfering
  • Receptors, Prolactin
  • SLC30A2 protein, human
  • Zinc